Banco Santander (SAN)
(Delayed Data from NYSE)
$5.01 USD
-0.06 (-1.18%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $5.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth D Momentum D VGM
Price, Consensus and EPS Surprise
SAN 5.01 -0.06(-1.18%)
Will SAN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SAN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SAN
SAN or NABZY: Which Is the Better Value Stock Right Now?
Banco Santander (SAN) Upgraded to Buy: Here's What You Should Know
SAN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Hartford Multifactor Developed Markets (ex-US) ETF (RODM) a Strong ETF Right Now?
SAN vs. SMFG: Which Stock Is the Better Value Option?
All You Need to Know About Banco Santander (SAN) Rating Upgrade to Strong Buy
Other News for SAN
Press Release: Availability of the Q3 2024 Aide memoire
Sanofi to highlight skin disease treatments at Amsterdam conference
Jill Biden reveals $500 million plan that focuses on women's health at Clinton Global Initiative
GLOBAL BROKER RATINGS: BofA cuts LVMH, Kering and Hugo Boss
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant